Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

3(30%)

Results Posted

75%(3 trials)

Terminated

2(20%)

Phase Distribution

Ph phase_1

30%

Ph phase_2

50%

Ph phase_3

10%

Ph not_applicable

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

3(30.0%)

Phase 2Efficacy & side effects

5(50.0%)

Phase 3Large-scale testing

1(10.0%)

N/ANon-phased studies

1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(4)

Terminated(3)

Detailed Status

Completed4

Recruiting2

Terminated2

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (30.0%)

Phase 25 (50.0%)

Phase 31 (10.0%)

N/A1 (10.0%)

Trials by Status

active_not_recruiting110%

withdrawn110%

recruiting220%

completed440%

terminated220%

Recent Activity

3 active trials

Showing 5 of 10

active_not_recruitingphase_2

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751

recruitingphase_3

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

NCT03643276

recruitingphase_2

Ma-Spore ALL 2020 Study

NCT06336395

terminatedphase_2

AflacLL1901 (CHOA-AML)

NCT04326439

terminatedphase_1

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

NCT00928200

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03117751Phase 2

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active Not Recruiting

NCT03643276Phase 3

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting

NCT06336395Phase 2

Ma-Spore ALL 2020 Study

Recruiting

NCT04326439Phase 2

AflacLL1901 (CHOA-AML)

Terminated

NCT00928200Phase 1

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Terminated

NCT02718755Phase 2

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Withdrawn

NCT02283190Phase 1

1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)

Completed

NCT00693602Phase 1

Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma

Completed

NCT00506597Not Applicable

Erwinase Study in Patients With Acute Lymphoblastic Leukemia

Completed

NCT00283985Phase 2

Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma

Completed

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10